MoonLake Immunotherapeutics
(NASDAQ) MLTX
MoonLake Immunotherapeutics Financials at a Glance
Market Cap
$1.41BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Revenue (TTM)
$0.00
Net Income (TTM)
-$257.08M
EPS (TTM)
-$3.87
P/E Ratio
-4.95
Dividend
$0.00
Beta (Volatility)
0.58 (Low)
Dividend
$0.00
Beta (Volatility)
0.58 (Low)
Price
$19.14
Volume
1,171
Open
$18.91
Price
$19.14
Volume
1,171
Open
$18.91
Previous Close
$19.15
Daily Range
$18.46 - $19.41
52-Week Range
$5.95 - $62.75
Estimated Earnings Date
Aug 4, 2026
Dividend
$0.00
Beta (Volatility)
0.58 (Low)
Price
$19.14
Volume
1,171
Open
$18.91
Previous Close
$19.15
Daily Range
$18.46 - $19.41
52-Week Range
$5.95 - $62.75
Estimated Earnings Date
Aug 4, 2026
MLTX News
MLTX: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout MoonLake Immunotherapeutics
Industry
Biotechnology
Sector
Health CareEmployees
130
CEO
Jorge Santos da Silva, PhD
Website
www.moonlaketx.comHeadquarters
Zug, ZG 6300, CH
MLTX Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-85.61%
Return on Capital
-64.40%
Return on Assets
-64.21%
Earnings Yield
-20.20%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.41BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Shares Outstanding
73.62M
Volume
1.17K
Avg. Volume
1.08M
Financials (TTM)
Gross Profit
-$2.34M
Operating Income
-$267.37M
EBITDA
-$245.81M
Operating Cash Flow
-$224.15M
Capital Expenditure
$0.00
Free Cash Flow
-$224.15M
Cash & ST Invst.
$357.92M
Total Debt
$100.80M
MoonLake Immunotherapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonCurrently no data to display.
Earnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
N/A
Gross Profit
-$845.00K
N/A
Gross Margin
0.00%
N/A
Market Cap
$1.41BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
N/A
Market Cap/Employee
$10.84M
N/A
Employees
130
N/A
Net Income
-$69.71M
-74.5%
EBITDA
-$65.97M
-64.9%
Quarterly Fundamentals
Total Cash
$357.92M
-25.5%
Total Debt
$100.80M
+33.3%
Accounts Receivable
$5.76M
+92.9%
Inventory
$0.00
N/A
Long Term Debt
$99.88M
+34.7%
Short Term Debt
$920.00K
-35.8%
Return on Assets
-64.21%
N/A
Return on Invested Capital
-75.47%
N/A
Free Cash Flow
-$66.29M
-73.6%
Operating Cash Flow
-$66.29M
-73.8%